Pentacel vaccine consists of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component as well as an ActHIB® vaccine component.
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b.
Pentacel is administered as an intramuscular injection.
Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday).
September 21, 2020 - Sanofi Pasteur, the largest biotech company in the world devoted entirely to vaccines, requested the agency’s approval for switching from using an aborted fetal cell line called MRC-5 to using an ethical animal cell line to produce its polio combination vaccines Pentacel and Quadracel.
June 23, 2008 - Sanofi Pasteur, announced that the U.S. Food and Drug Administration (FDA) has licensed Pentacel® vaccine that is approved for use in infants and children 6 weeks through 4 years of age (prior to the fifth birthday). Pentacel® vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.